Tacrolimus Exposure Before and After a Switch From Twice-Daily Immediate-Release to Once-Daily Prolonged Release Tacrolimus: The ENVARSWITCH Study.

"Conflict of Interest CMo reports receiving lecture fees and support for participation in International Congress from Astellas. SD reports receiving lecture fees from Chiesi, Novartis, Sandoz, Intercept, Astellas, Roche, Ipsen and Abbvie and serving as a board member of Novartis and Biotest. AT reports a research grant from Astellas. MB reports financial support from Chiesi for participation in International Congress. CG has received consulting fees from Chiesi and speaker’s honoraria from Astellas. DA has received travel grant and honoraria for lectures from Chiesi. FS has received speaker’s honoraria and/or research grants from Chiesi, Novartis, Astellas, Gilead, Neovii, Merck Sharp & Dohme, Pfizer and Baxter. CMa reports research grants, financial support for participation in congresses and expertise fees from Chiesi and Astellas. PMa has received speaker and consultant honoraria and/or research grants from Chiesi, Sandoz, Astellas and BMS. The remaining authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest. "

"The authors declare that this study received funding from Chiesi SAS France, Bois-Colombes, France. The funder was not involved in the study design, collection, analysis, interpretation of data, the writing of this article or the decision to submit it for publication."